Individualizing Corticosteroid Use in Pneumonia
Key facts
- Who runs it
- Mayo Clinic
- Where
- Rochester, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 24 people enrolled
- Started
- 6 Nov 2024
- Ended
- 29 Apr 2026
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Dexamethasone
- Record updated
- 5 August 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Hospitalized adult (≥ 18 years) patients
- Community acquired pneumonia
Who cannot take part
- Contraindications or unwillingness to use corticosteroids by patient or provider
- History of adrenal insufficiency, septic shock, or another absolute indication for steroid use
- Suspected pulmonary vasculitis or other autoimmune pulmonary disorder
- Positive pregnancy test
- Comfort care
Where in United States
- Mayo Clinic - RochesterRochester, United States
About the trial
What the trial wants to find out
In this study, researchers propose a unique (individualized) approach to steroid treatment seeking to give the right dose of steroid to the right patient and at the right time. This study seeks to compare usual care to an individualized steroid dosing strategy by testing a marker of inflammation in the blood called C- reactive protein (CRP). The overall goal is to reduce an individual's exposure to steroids and the risk of potential side effects thereby increasing the potential benefit of using steroids to control inflammation in pneumonia.
The 2 groups in the trial
- Usual Care GroupNo study treatment, for comparison
Usual care as determined by the patient's primary team. Initiation and daily dosing of corticosteroid treatment will be based on clinicians' preference and clinicians.
- Individualized dosing strategyTreatment being tested
Biomarker guided corticosteroid use. Initiation of corticosteroid will be recommended based on the an individual treatment rule (ITR) and subsequent dosing of corticosteroid will be recommended based on daily CRP values till CRP \<50 mg/L (according to a prespecified C-reactive protein-guided dosing algorithm). Corticosteroid dose and duration were determined by serial CRP measurements The approved protocol included CRP-guided corticosteroid dosing as a prespecified contingency strategy if a clinically actionable individualized treatment rule could not be developed. The trial therefore proceeded with the CRP-guided corticosteroid strategy
Treatment: Dexamethasone
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 5 August 2026